Name | terazosin |
Synonyms | Urodie terazosin Terazosina Terazosinum UNII-8L5014XET7 TERAZOSIN(HYTRIN) Prazosin Tetrahydro IMpurity 1-(4-aMino-6,7-diMethoxy-quinazolin-2-yl)-4-(tetrahydrofuran-2-carbonyl)-piperazine Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)- 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl) carbonxyl] piperazine hydrochloride [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone chloride dihydrate |
CAS | 63590-64-7 |
EINECS | 613-265-8 |
InChI | InChI=1/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2/p-1 |
InChIKey | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
Molecular Formula | C19H25N5O4 |
Molar Mass | 387.43 |
Density | 1.332±0.06 g/cm3(Predicted) |
Melting Point | 281-283°C |
Boling Point | 664.5±65.0 °C(Predicted) |
Water Solubility | 30.6mg/L(22.5 ºC) |
Solubility | H2O: 25mg/mL |
Appearance | powder |
Color | white to off-white |
pKa | pKa (0.1N NaOH): 7.1(at 25℃) |
Storage Condition | -20°C Freezer |
MDL | MFCD00467965 |
Physical and Chemical Properties | Fine white crystals, odorless and tasteless, melting point 272.6~174 ℃. Solubility (mg/m1) at 25 ° C.: methanol 33.7, water 29.7,95% ethanol 4.1,0.1mol/L hydrochloric acid 3,8, chloroform 1.2, acetone 0.01. Insoluble in hexane. UV absorption maximum (0.005% water):212,245,330nm(a 65.7,127.5,24.0). pKa(0.1mol/L sodium hydroxide) 7.1. Terazosin Hydrochloride: C19H25N5O4? HCl. Crystallization from isopropanol, hygroscopic. The melting point was 278-279 °c. Soluble in water: 761.2mg/ml. Acute toxicity LD50 mice (mg/kg):259.3 I. V. Terazosin hydrochloride dihydrate: C19H25N5O4? HCl? 2H2O. [70024-40-7]. The melting point was 271-274 °c. Soluble in water: 24.2mg/ml. Acute toxicity LD50 male and female rats (mg/kg):277,293 intravenous injection. |
In vitro study | Terazosin does not discriminate cloned α1-adrenoceptor subtypes transiently expressed in COS cells. |
In vivo study | Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm. |
Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
RTECS | TK8044925 |
micro-white crystal, odorless and tasteless, melting point 272.6~174 ℃. Solubility (mg]mL) at 25 °c: methanol 33.7, water 29.7, ethanol 95% 4.1, hydrochloric acid 0.1 3.8 mol/L, chloroform 1.2, acetone 0. 01. Practically insoluble in hexane. UV maximum absorption (0. oos% water):212, 245, 330nm (a 65.7,127.5, pKA (0.1mol/L sodium hydroxide) 7.1.
with furoic acid as raw material, using thionyl chloride chlorination to produce furoyl chloride, and then the monoacylation of piperazine, monoacyl product after reduction with 4-amino -2-chlorine -6, the condensation of 7-methoxyquinazoline in the presence of triethylamine yields terazosin. Acidification with hydrochloric acid in ethanol yields terazosin hydrochloride containing two water of crystallization.
is a quinazoline derivative, a-receptor blocker, has a good hypotensive effect. For primary mild to moderate hypertension and hypertension caused by cell tumor. Selective a1 adrenergic receptor blockers, can reduce the bladder outlet smooth muscle tension, relieve prostatic hyperplasia due to smooth muscle tension caused by dysuria. Can also reduce the resistance of the surrounding blood vessels, so that blood pressure drops.
terazosin hydrochloride: Mouse intravenous injection LD50 (mg/kg):259.3. Terazosin dihydrate: male and female rats intravenous LDso (mg]kg):277,293.
biological activity | Terazosin is a quinazoline derivative, it is also a competitive and orally active α1-adrenoceptor antagonist. Terazosin acts by dilating blood vessels and opening the bladder. Terazosin can be used in the study of benign prostatic hyperplasia (BPH) and hypertension. |
Target | α1-adrenoptor |
Application | is quinazoline derivative, α1-adrenoceptor blocker, with good hypotensive effect. For renal, primary mild to moderate hypertension and hypertension caused by cell tumor. antihypertensive drugs. |
production method | using furoic acid as raw material, using thionyl chloride to produce furfuryl chloride, the monoacylation product is reduced and condensed with 4-amino-2-chloro-6, 7-dimethoxyquinazoline in the presence of triethylamine to give terazosin. Acidification with hydrochloric acid in ethanol yields terazosin hydrochloride containing two water of crystallization. |